Evaluating the Efficacy of mRNA Vaccine Platforms in Emerging Infectious Disease Control
Keywords:
mRNA vaccine, infectious disease control, immunogenicity, vaccine efficacy, pandemic response, public health, viral outbreaksAbstract
Messenger RNA (mRNA) vaccine platforms have emerged as a transformative tool in the global response to infectious diseases, offering unprecedented speed and adaptability in vaccine development. This paper evaluates the efficacy of mRNA-based vaccines in controlling emerging infectious diseases through analysis of immunogenicity, safety profiles, scalability, and population-level outcomes. The study synthesizes data from preclinical and clinical trials, public health surveillance, and real-world evidence to assess how mRNA platforms have reshaped vaccine deployment. Emphasis is placed on their role in mitigating viral outbreaks with pandemic potential, such as SARS-CoV-2, and their application in preparedness strategies for future zoonotic threats. The findings highlight both the success and the current limitations of mRNA technologies, with implications for global health policy, vaccine equity, and future platform development.
References
Karikó, Katalin, et al. “Suppression of RNA Recognition by Toll Like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA.” Immunity, vol. 23, no. 2, 2005, pp. 165–175.
Pardi, Norbert, et al. “mRNA Vaccines—A New Era in Vaccinology.” Nature Reviews Drug Discovery, vol. 17, no. 4, 2018, pp. 261–279.
Polack, Fernando P., et al. “Safety and Efficacy of the BNT162b2 mRNA COVID 19 Vaccine.” New England Journal of Medicine, vol. 383, no. 27, 2020, pp. 2603–2615.
Baden, Lindsey R., et al. “Efficacy and Safety of the mRNA 1273 SARS CoV 2 Vaccine.” New England Journal of Medicine, vol. 384, no. 5, 2021, pp. 403–416.
Weissman, Drew, and Katalin Karikó. “mRNA Vaccine Developments: Advancing the Field.” Annual Review of Medicine, vol. 72, 2021, pp. 261–274.
Hou, Xiaoying, et al. “Lipid Nanoparticles for mRNA Delivery.” Nature Reviews Materials, vol. 6, no. 12, 2021, pp. 1078–1094.
Zhang, Chao, et al. “Advances in mRNA Vaccines for Infectious Diseases.” Frontiers in Immunology, vol. 12, 2021, pp. 1–15.
Feldman, Rachel A., et al. “mRNA Vaccines Against Influenza: Progress and Potential.” Vaccine, vol. 37, no. 25, 2019, pp. 3326–3334.
Richner, Justin M., et al. “Modified mRNA Vaccines Protect Against Zika Virus Infection.” Nature, vol. 543, no. 7644, 2017, pp. 248–251.
Schnee, Markus, et al. “A Novel mRNA-Based Rabies Vaccine Induces Potent Immune Responses.” Vaccine, vol. 34, no. 37, 2016, pp. 4647–4654.
Sahin, Ugur, et al. “mRNA-Based Therapeutic Vaccines for Cancer and Infectious Diseases.” Molecular Therapy, vol. 22, no. 4, 2014, pp. 692–701.
Blakney, Anna K., et al. “The Future of RNA Vaccines: Innovations and Applications.” Expert Opinion on Biological Therapy, vol. 21, no. 6, 2021, pp. 1–15.
Downloads
Published
Issue
Section
License
Copyright (c) -1 Archie Edward Young (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
